

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Williams Rosemary Y.</u> (Last) (First) (Middle) <u>C/O BELLICUM PHARMACEUTICALS, INC.</u> <u>2130 W. HOLCOMBE BLVD., STE. 800</u> (Street) <u>HOUSTON TX 77030</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/16/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>BELLICUM PHARMACEUTICALS, INC [BLCM]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Principal Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
--	---	--	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,186</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Stock Option (right to buy)</u>	<u>(1)</u>	<u>04/30/2024</u>	<u>Common Stock</u>	<u>17,647</u>	<u>2.55</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(2)</u>	<u>10/27/2024</u>	<u>Common Stock</u>	<u>11,764</u>	<u>7.47</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(3)</u>	<u>02/23/2025</u>	<u>Common Stock</u>	<u>14,000</u>	<u>23.47</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(4)</u>	<u>01/03/2026</u>	<u>Common Stock</u>	<u>15,000</u>	<u>19</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(5)</u>	<u>01/02/2027</u>	<u>Common Stock</u>	<u>5,625</u>	<u>13.89</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(6)</u>	<u>07/02/2027</u>	<u>Common Stock</u>	<u>13,125</u>	<u>11.7</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(7)</u>	<u>01/01/2028</u>	<u>Common Stock</u>	<u>9,225</u>	<u>9.23</u>	<u>D</u>
<u>Stock Option (right to buy)</u>	<u>(8)</u>	<u>07/01/2028</u>	<u>Common Stock</u>	<u>21,525</u>	<u>7.72</u>	<u>D</u>
<u>Restricted Stock Units</u>	<u>(9)</u>	<u>(9)</u>	<u>Common Stock</u>	<u>2,344</u>	<u>(10)</u>	<u>D</u>
<u>Restricted Stock Units</u>	<u>(11)</u>	<u>(11)</u>	<u>Common Stock</u>	<u>5,125</u>	<u>(10)</u>	<u>D</u>

Explanation of Responses:

1. 25% of the shares subject to the stock option vest and become exercisable on May 1, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
2. 25% of the shares subject to the stock option vest and become exercisable on October 28, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
3. 25% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
4. 25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
5. 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
6. 25% of the shares subject to the stock option vest and become exercisable on July 03, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
7. 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
8. 25% of the shares subject to the stock option vest and become exercisable on July 02, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
9. On January 3, 2017, the reporting person was granted restricted stock units (the "RSUs") for 3,125 shares. The RSUs vest in four annual installments beginning on January 3, 2018.
10. Each RSU represents a contingent right to receive one share of the Issuer common stock.
11. On January 2, 2018, the reporting person was granted the RSUs for 5,125 shares. The RSUs vest in four equal annual installments beginning on January 2, 2019.

Remarks:

Rosemary Y. Williams

01/04/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.